Evaluation of a surrogate marker: validity and efficiency
Statistics in Medicine2012Vol. 32(12), pp. 1995–2000
Citations Over TimeTop 10% of 2012 papers
Abstract
Statistical validation of a surrogate endpoint or surrogate marker has been studied for three decades. However, there is still no consensus on how to evaluate surrogate endpoints or surrogate markers. There is much confusion on which method should be used for the evaluation of a surrogate endpoint or surrogate marker. In this article, we clarify the statistical definitions of the surrogate endpoint and surrogate marker and introduce the concept of the validity and efficiency of a surrogate marker. We suggest the proportion of information gain can be used to evaluate the validity of a surrogate marker.
Related Papers
- → Surrogate endpoints in clinical trials: Cancer(1989)160 cited
- → Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials(2016)15 cited
- → Evaluation of a surrogate marker: validity and efficiency(2012)6 cited
- On the use of laboratory markers as surrogates for clinical endpoints in the evaluation of treatment for HIV infection.(1990)
- [Surrogate endpoints].(1999)